3 Scorned Biotech Stocks Poised For a Rebound

August hit the biotech industry hard, but all hope is not lost; following are several biotech companies that look as though they’ll rebound. The trends to look for are as follows: acquisition of additional pharmaceutical/biotech agencies, development of treatment options which pass clinical trials, and development of treatments for conditions which previously had no treatment. Akebia and Valadustat Akebia Therapeutics (AKBA) has seen some very heartening results during the clinical trials for valadustat. For patients forced into renal dialysis, valadustat is a drug which aids in proper blood levels, ensuring hemoglobin is at the correct saturation. As a result,...

Read More

Biotech Stock Investing 101 – What to Look For?

Buying stocks in the biotech industry can be very complicated. Following are some basic tips to help you get started. Acquisitions Look for companies that are making acquisitions. An organization that is making a purchase should ideally have some solid foundation, as well. Acquisitions do happen quite a lot, but when a company is looking to buy another one, and there is substantial money involved, you can bet those making the purchase believe it’s going to be lucrative to them. The higher the cost they pay to acquire another company, the more likely it is that their stock is...

Read More

Analysts Set $6.00 Price Target for Sinovac Biotech Ltd. (NASDAQ:SVA)

Biotech organizations are a more and more steady investment today, and Sinovac is a biopharmaceutical company whose focus on research and development is strengthened by further manufacture and commercialization of various vaccinations. Hepatitis A and B are among the vaccinations offered by Sinovac, but one of the most well-known is going to be seasonal influenza. Investing in organizations that purvey flu shots is a fairly steady kind of investment, provided the organization is like Sinovac and is showing strong numerical increase over time. Sinovac also has inoculations against mumps, animal rabies, H5N1, pandemic influenza, the H1N1 virus, and various...

Read More

The Never Ending War on Cancer

There is a certain insidious truth to the title of this piece. The war on cancer is a never-ending one, because cancer is multifaceted, and there isn’t any one specific type of cure. Furthermore, internationally modernity encourages behavior that systematically facilitates the development of cancerous ailments. From alcoholism to smoking, from untested genetically modified foodstuffs to aspartame and its cancer/Alzheimer’s linkage, and even negative health developments which stem from technology use, cancer isn’t just a genetic predisposition. Radiation, medication, and a marked lack of exercise also characterize cancerous populations. As a result, biotech companies facilitating demonstrably effective cancer treatments...

Read More

Buying Biotech Stock Shows Big Losses & Massive Gains: How To Stay Ahead?

Biotech companies that know how to acquire the right assets are the companies that you want to acquire.  Alexion Pharmaceuticals is a company that a firm like Goldman Sachs has generally gone cold on in recent years. But you may have to look at the entire industry before you automatically discard Alexion.  Cash Return on Invested Capital is something that you are going to want to survey when you are evaluating a stock.  Firms are beginning to spend more on research and development.  Swedish biotechnology firms spent around 4.1 million dollars on research and development alone.  You may want...

Read More